Characteristics of the included donors
| rs772557 . | Donor type . | n (m:f) . | Median age, y (range) . | Median weight, kg (range) . | Median BMI (range) . | Donor relationship . | Donor diagnosis . | Median CD34+ level cells per μL (range) . | G-CSF+ . | Plerixafor+ . | Harvest day+ . | No harvest . | Median CD34+ yield (range) . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related . | Unrelated . | MM . | Other . | Pre . | Post . | Ratio . | |||||||||||
| GG | Allogeneic | 7 (5:2) | 28 (21-42) | 80 (64-125) | 24.4 (22.1-37.3) | 3 | 5 | n/a | n/a | 2.3 (1.9-3.5) | 21.8 (15.3-67.9) | 8.4 (5.1-33.2) | 3 | 1 | 0 | 0 | 8.4 (5.8-11) |
| Autologous | 10 (6:4) | 61 (41-71) | 76 (60-106) | 25.8 (22.6-32.7) | n/a | n/a | 8 | 2 | 0.8 (0.3-2.2) | 10.5 (1-45.7) | 10 (0.1-36.6) | 7 | 8 | 1 | 0 | 4.7 (3.3-11.6) | |
| AG | Allogeneic | 15 (12:3) | 29 (19-55) | 78 (62-105) | 24.4 (20.2-30.1) | 1 | 14 | n/a | n/a | 1.9 (0.9-10.7) | 38.9 (12-114.3) | 16.9 (3-64) | 3 | 0 | 1 | 0 | 7.3 (3.2-15.1) |
| Autologous | 27 (20:7) | 60 (38-69) | 81 (58-104) | 25.7 (19.8-36.7) | n/a | n/a | 19 | 8 | 0.8 (0.2-6.7) | 8.9 (0.6-26) | 7.6 (0.1-26.6) | 16 | 17 | 1 | 3 | 4.1 (2.4-8.9) | |
| AA | Allogeneic | 8 (6:2) | 27 (20-38) | 79 (58-116) | 24.4 (18.8-32.5) | 0 | 8 | n/a | n/a | 2.2 (0.5-5.1) | 47.8 (12-76.9) | 23 (6.9-75) | 1 | 0 | 0 | 0 | 7.6 (3.3-15.9) |
| Autologous | 19 (11:8) | 61 (43-70) | 70 (50-109) | 24.8 (19.9-35-2) | n/a | n/a | 16 | 3 | 1 (0.2-8.8) | 5.5 (1.6-19.2) | 4.9 (0.3-19.7) | 15 | 15 | 1 | 1 | 3.6 (2-14) | |
| Total | Allogeneic | 31 (23:8) | 29 (19-55) | 78 (58-125) | 24.4 (20.1-37.3) | 4 | 27 | n/a | n/a | 2.1 (0.5-10.7) | 34.2 (12.1-114.3) | 15.4 (3-75.1) | 7 | 1 | 1 | 0 | 7.3 (3.2-15.9) |
| Autologous | 56 (37:19) | 60 (38-70) | 77 (50-109) | 24.8 (18.8-36.7) | n/a | n/a | 43 | 13 | 0.8 (0.2-8.8) | 8 (0.6-46.6) | 7.4 (0.1-49.5) | 39 | 41 | 3 | 4 | 3.9 (1.3-14) | |
| rs772557 . | Donor type . | n (m:f) . | Median age, y (range) . | Median weight, kg (range) . | Median BMI (range) . | Donor relationship . | Donor diagnosis . | Median CD34+ level cells per μL (range) . | G-CSF+ . | Plerixafor+ . | Harvest day+ . | No harvest . | Median CD34+ yield (range) . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related . | Unrelated . | MM . | Other . | Pre . | Post . | Ratio . | |||||||||||
| GG | Allogeneic | 7 (5:2) | 28 (21-42) | 80 (64-125) | 24.4 (22.1-37.3) | 3 | 5 | n/a | n/a | 2.3 (1.9-3.5) | 21.8 (15.3-67.9) | 8.4 (5.1-33.2) | 3 | 1 | 0 | 0 | 8.4 (5.8-11) |
| Autologous | 10 (6:4) | 61 (41-71) | 76 (60-106) | 25.8 (22.6-32.7) | n/a | n/a | 8 | 2 | 0.8 (0.3-2.2) | 10.5 (1-45.7) | 10 (0.1-36.6) | 7 | 8 | 1 | 0 | 4.7 (3.3-11.6) | |
| AG | Allogeneic | 15 (12:3) | 29 (19-55) | 78 (62-105) | 24.4 (20.2-30.1) | 1 | 14 | n/a | n/a | 1.9 (0.9-10.7) | 38.9 (12-114.3) | 16.9 (3-64) | 3 | 0 | 1 | 0 | 7.3 (3.2-15.1) |
| Autologous | 27 (20:7) | 60 (38-69) | 81 (58-104) | 25.7 (19.8-36.7) | n/a | n/a | 19 | 8 | 0.8 (0.2-6.7) | 8.9 (0.6-26) | 7.6 (0.1-26.6) | 16 | 17 | 1 | 3 | 4.1 (2.4-8.9) | |
| AA | Allogeneic | 8 (6:2) | 27 (20-38) | 79 (58-116) | 24.4 (18.8-32.5) | 0 | 8 | n/a | n/a | 2.2 (0.5-5.1) | 47.8 (12-76.9) | 23 (6.9-75) | 1 | 0 | 0 | 0 | 7.6 (3.3-15.9) |
| Autologous | 19 (11:8) | 61 (43-70) | 70 (50-109) | 24.8 (19.9-35-2) | n/a | n/a | 16 | 3 | 1 (0.2-8.8) | 5.5 (1.6-19.2) | 4.9 (0.3-19.7) | 15 | 15 | 1 | 1 | 3.6 (2-14) | |
| Total | Allogeneic | 31 (23:8) | 29 (19-55) | 78 (58-125) | 24.4 (20.1-37.3) | 4 | 27 | n/a | n/a | 2.1 (0.5-10.7) | 34.2 (12.1-114.3) | 15.4 (3-75.1) | 7 | 1 | 1 | 0 | 7.3 (3.2-15.9) |
| Autologous | 56 (37:19) | 60 (38-70) | 77 (50-109) | 24.8 (18.8-36.7) | n/a | n/a | 43 | 13 | 0.8 (0.2-8.8) | 8 (0.6-46.6) | 7.4 (0.1-49.5) | 39 | 41 | 3 | 4 | 3.9 (1.3-14) | |
Other diagnoses include light-chain amyloidosis (n = 3), B-cell lymphoma (n = 6), T-cell lymphoma (n = 1), Waldenström disease (n = 1), isolated extramedullary plasmacytoma (n = 1), plasma cell leukemia (n = 1), Hodgkin lymphoma and MM (n = 1). G-CSF+ includes donors receiving additional G-CSF therapy to reach CD34+ yield. Plerixafor+ includes donors receiving additional plerixafor (CXCR4 inhibitor) to reach CD34+ yield. Harvest day+ refers to donors requiring an additional day of harvest (receiving additional G-CSF and/or plerixafor). No harvest refers to donors from whom no stem cells were collected. Pre refers to before mobilization therapy. Post refers to after mobilization therapy. Ratio represents mobilization efficiency.
BMI, body mass index; f, female; m, male; MM, multiple myeloma; n/a, not available.